Antenatal management for patients with increased risk of post-partum hemorrhage (excluding abnormal placentatio;Prise en charge anténatale des patientes à risque d'hémorragie du post-partum (hors anomalies de l'insertion placentaire)

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 43, Issue 10, 2014, Pages 951-965

  Fournet Fayard, A ^a   Lebreton, A ^a   Ruivard, M ^a,b   Storme, B ^a   Godeau, B ^c   Bonnin, M ^a   Delabaere, A ^b,d   Gallot, D ^b,d  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d Estaing Hospital   (France)

Author keywords

Anemia; Anticoagulanttherapy; Bleeding disorders; Immunethrombocytopenicpurpura; Orientation; Post partumhemorrhage; Prenatalmanagement

Indexed keywords

IRON;

ANALGESIA; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING DISORDER; BLOOD; FEMALE; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; POSTPARTUM HEMORRHAGE; PRENATAL CARE; THROMBOCYTOPENIA; OBSTETRIC LABOR COMPLICATIONS; PLACENTA DISEASES; PREGNANCY;

FEMALE; HUMANS; OBSTETRIC LABOR COMPLICATIONS; PLACENTA DISEASES; POSTPARTUM HEMORRHAGE; PREGNANCY;

EID: 84920039164     PISSN: 03682315     EISSN: 17730430     Source Type: Journal    
DOI: 10.1016/j.jgyn.2014.10.006     Document Type: Article

References (64)

1. Arulkumaran S, Mavrides E, Penney G. Prevention and manage-ment of postpartum haemorrhage. Green-top Guideline No. 52. Royal College of Obstetricians and Gynaecologists 2009: 1-24.
2. Upadhyay K, Scholefield H. Risk management and medicolegalissues related to postpartum haemorrhage. Best Prac Res ClinObstet Gynaecol 2008; 22: 1149-69.
3. Dunkley S, Russell S, Rowell J, Barnes C, Baker R, Sarson M, et al. A consensus statement on the management of pregnancyand delivery in women who are carriers of or have bleedingdisorders. Med J Aust 2009; 191: 460-3.
4. Huq F, Kadir R. Management of pregnancy, labour and deli-very in women with inherited bleeding disorders. Haemophilia2011; 17: 20-30.
5. Deruelle P, Coulon C, Vaast P, Houfflin-Debarge V. Grossessesgémellaires: où les suivre ? Où les faire accoucher ? J GynecolObstet Biol Reprod 2009; 38: S56-60.
6. Bayoumeu F, Verspyck E. Prise en charge anténatale: la gestiondu risque. J Gynecol Obstet Biol Reprod 2004; 33, 4S17-28.
7. Singla A, Lapinski R, Berkowitz R, Saphier C. Are women whoare Jehovah's Witnesses at risk of maternal death? Am J ObstetGynecol 2001; 185: 893-5.
8. Massiah N, Athimulam S, Loo C, Okolo S, Yoong W. Obstetriccare of Jehovah's Witnesses: a 14-year observational study. Arch Gynecol Obstet 2007; 276: 39-43.
9. Van Wolfswinkel M, Zwart J, Schutte J, Duvekot J, Pel M, Van Roosmalen J. Maternal mortality and serious maternalmorbidity in Jehovah's witnesses in The Netherlands. BJOG2009; 116: 1103-8.
10. Gupta S, Onwude J, Stasi R, Manyonda I. Refusal of bloodtransfusion by Jehovah's Witness women: a survey of currentmanagement in obstetric and gynaecological practice in theUK. Blood Transfus 2012; 10: 462-70.
11. Djoudi R. Gestion des produits sanguins en maternité. JGynecol Obstet Biol Reprod (Paris) 2014, http://dx.doi.org/10.1016/j.jgyn.2014.10.006.
12. Haute Autorité de santé. Suivi et orientation des femmesenceintes en fonction des situations à risque identifiées. Synthèse des recommandations professionnelles (mai 2007). Gynecol Obstet Fertil 2008; 36: 111-4.
13. Molliex S, Pierre S, Bléry C, Marret E, Beloeil H. Examenspréinterventionnels systématiques. Ann Fr Anesth Reanim2012; 31: 752-63.
14. Beucher G, Grossetti E, Simonet T, Leporrier M, Dreyfus M. Anémie par carence martiale et grossesse. Prévention et trai-tement. J Gynecol Obstet Biol Reprod 2011; 40: 185-200.
15. Arlet J, Pouchot J, Lasocki S, Beaumont C, Hermine O. Supplé-mentation en fer: indications, limites et modalités. Rev MedInterne 2013; 34: 26-31.
16. Tosetto A, Castaman G, Rodeghiero F. Assessing bleedingin von Willebrand disease with bleeding score. Blood Rev2007; 21: 89-97.
17. Sfar. Les blocs périmédullaires chez l'adulte. Recommanda-tions pour la Pratique Clinique; 2006.
18. Pena-Rosas J, De-Regil L, Dowswell T, Viteri F. Daily oral ironsupplementation during pregnancy. Cochrane Database SystRev 2012; 12: CD004736.
19. Wang J, Klein H. Red blood cell transfusion in the treatment andmanagement of anaemia: the search for the elusive transfusiontrigger. Vox Sang 2010; 98: 2-11.
20. Clark V, Waters J. Blood transfusions: more is not necessarilybetter. Int J Obstet Anesth 2009; 18: 299-301.
21. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D, et al. Standardization of terminology, definitionsand outcome criteria in immune thrombocytopenic purpuraof adults and children: report from an international workinggroup. Blood 2009; 113: 2386-93.
22. Boehlen F, Hohlfeld P, Extermann P, Perneger T, De MoerlooseP. Platelet count at term pregnancy: a reappraisal of the thre-shold. Obstet Gynecol 2000; 95: 29-33.
23. Khellaf M, Loustau V, Bierling P, Michel M, Godeau B. Thrombo-pénie et grossesse. Rev Med Interne 2012; 33: 446-52.
24. Debouverie O, Roblot P, Roy-Péaud F, Boinot C, Pierre F, Pourrat O. Évolution d'une thrombopénie chronique idiopa-thique en cours de grossesse (62 grossesses). Rev Med Interne2012; 33: 426-32.
25. Haute Autorité de santé. Purpura thrombopénique immuno-logique de l'enfant et de l'adulte. Protocole national dediagnostic et de soins; 2009.
26. Provan D, Stasi R, Newland A, Blanchette V, Bolton-Maggs P, Bussel J, et al. International consensus report on the investiga-tion and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86.
27. Gernsheimer T, James A, Stasi R. How I treat thrombocytopeniain pregnancy. Blood 2013; 121: 38-47.
28. Godeau B, Chevret S, Varet B, Lefrère F, Zini J, BassompierreF, et al. Intravenous immunoglobulin or high-dose methylpred-nisolone, with or without oral prednisone, for adults withuntreated severe autoimmune thrombocytopenic purpura: arandomised, multicentre trial. Lancet 2002; 359: 23-9.
29. Bolton-Maggs P, Perry D, Chalmers E, Parapia L, Wilde J, Williams M, et al. The rare coagulation disorders-reviewwith guidelines for management from the United King-dom Haemophilia Centre Doctors' Organisation. Haemophilia2004; 10: 593-628.
30. Demers C, Derzko C, David M, Douglas J, Society of Obs-tetricians and Gynaecologists of Canada. Gynaecological andobstetric management of women with inherited bleeding disor-ders. Int J Gynaecol Obstet 2006; 95: 75-87.
31. Lee C, Chi C, Pavord S, Bolton-Maggs P, Pollard D, Hinchcliffe-Wood A, et al. The obstetric and gynaecological managementof women with inherited bleeding disorders-review with gui-delines produced by a taskforce of UK Haemophilia CentreDoctors' Organization. Haemophilia 2006; 12: 301-36.
32. James A, Kouides P, Abdul-Kadir R, Edlund M, Federici A, Halimeh S, et al. Von Willebrand disease and other bleedingdisorders in women: consensus on diagnosis and managementfrom an international expert panel. Am J Obstet Gynecol2009; 201: 12, e1-8.
33. James A. Guidelines for bleeding disorders in women. ThrombRes 2009; 123: S124-8.
34. James A. Diagnosis and management of women with bleedingdisorders-international guidelines and consensus from an inter-national expert panel. Haemophilia 2011; 17: 3-5.
35. James A, Jamison M. Bleeding events and other complicationsduring pregnancy and childbirth in women with von Willebranddisease. J Thromb Haemost 2007; 5: 1165-9.
36. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B. Preva-lence and risk factors of severe obstetric haemorrhage. BJOG2008; 115: 1265-72.
37. Peyvandi F, Garagiola I, Menegatti M. Gynecological and obste-trical manifestations of inherited bleeding disorders in women. J Thromb Haemost 2011; 9: 236-45.
38. Nichols W, Hultin M, James A, Manco-Johnson M, Montgomery R, Ortel T, et al. von Willebrand disease (VWD): evidence-baseddiagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
39. Prendiville W, Harding J, Elbourne D, Stirrat G. The Bristol thirdstage trial: active versus physiological management of thirdstage of labour. BMJ 1988; 297: 1295-300.
40. Dahlman T, Hellgren M, Blombäck M. Changes in blood coagula-tion and fibrinolysis in the normal puerperium. Gynecol ObstetInvest 1985; 20: 37-44.
41. Huq F, Kulkarni A, Agbim E, Riddell A, Tuddenham E, Kadir R. Changes in the levels of factor VIII and von Willebrand factorin the puerperium. Haemophilia 2012; 18: 241-5.
42. Kadir R, Economides D, Braithwaite J, Goldman E, Lee C. Theobstetric experience of carriers of haemophilia. Br J ObstetGynaecol 1997; 104: 803-10.
43. Mauser Bunschoten E, Van Houwelingen J, Sjamsoedin Visser E, Van Dijken P, Kok A, Sixma J. Bleeding symptoms in carriers ofhemophilia A and B. Thromb Haemost 1988; 59: 349-52.
44. Siddiq S, Clark A, Mumford A. A systematic review of themanagement and outcomes of pregnancy in Glanzmann throm-basthenia. Haemophilia 2011; 17: e858-69.
45. Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham E, Kadir R. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010; 16: 584-91.
46. Mannucci P, Duga S, Peyvandi F. Recessively inherited coagula-tion disorders. Blood 2004; 104: 1243-52.
47. Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleedingdisorders. Haemophilia 2009; 15: 990-1005.
48. Peyvandi F, Menegatti M, Siboni S. Post-partum hemor-rhage in women with rare bleeding disorders. Thromb Res2011; 127: S116-9.
49. Guyatt G, Akl E, Crowther M, Gutterman D, Schuunemann H. Executive summary: Antithrombotic Therapy and Pre-vention of Thrombosis, 9th ed: American College of ChestPhysicians Evidence-Based Clinical Practice Guidelines. Chest2012; 141: 7S-47S.
50. Horlocker T. Regional anaesthesia in the patient recei-ving antithrombotic and antiplatelet therapy. Br J Anaesth2011; 107: i96-106.
51. Kreppel D, Antoniadis G, Seeling W. Spinal hematoma: a litera-ture survey with meta-analysis of 613 patients. Neurosurg Rev2003; 26: 1-49.
52. Duhl A, Paidas M, Ural S, Branch W, Casele H, Cox-Gill J, et al. Antithrombotic therapy and pregnancy: consensus reportand recommendations for prevention and treatment of venousthromboembolism and adverse pregnancy outcomes. Am J Obs-tet Gynecol 2007; 197: e451-521.
53. Bates S, Greer I, Pabinger I, Sofaer S, Hirsh J, American Collegeof Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College ofChest Physicians Evidence-Based Clinical Practice Guidelines(8th Edition). Chest 2008; 133: 844S-86S.
54. Roeters Van Lennep J, Meijer E, Klumper F, Middeldorp J, Bloemenkamp K, Middeldorp S. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy andpostpartum: is it effective? J Thromb Haemost 2011; 9: 473-80.
55. Horlocker T, Wedel D, Rowlingson J, Enneking F, Kopp S, BenzonH, et al. Regional anesthesia in the patient receiving antithrom-botic or thrombolytic therapy: American Society of RegionalAnesthesia and Pain Medicine Evidence-Based Guidelines (ThirdEdition). Reg Anesth Pain Med 2010; 35: 64-101.
56. Aiono-Le Tagaloa L, Carvalho B. Epidural labor analgesiain a patient receiving fondaparinux. Int J Obstet Anesth2009; 18: 94-5.
57. Llau J. Epidural labor analgesia in a patient receiving fondapa-rinux. Int J Obstet Anesth 2009; 18: 288-9.
58. Butwick A, Carvalho B. Neuraxial anesthesia in obstetricpatients receiving anticoagulant and antithrombotic drugs. IntJ Obstet Anesth 2010; 19: 193-201.
59. Mclintock C, Mccowan LM, North RA. Maternal complicationsand pregnancy outcome in women with mechanicalprosthetic heart valves treated with enoxaparin. BJOG2009; 116: 1585-92.
60. European Society of Gynecology, Association for EuropeanPaediatric Cardiology, German Society for Gender Medi-cine, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovasculardiseases during pregnancy: the Task Force on the Manage-ment of Cardiovascular Diseases during Pregnancy of theEuropean Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147-97.
61. Mclintock C. Anticoagulant therapy in pregnant women withmechanical prosthetic heart valves: no easy option. ThrombRes 2011; 127: S56-60.
62. Elfaghi I, Johansson-Ernste B, Rydhstroem H. Rupture of thesphincter ani: the recurrence rate in second delivery. BJOG2004; 111: 1361-4.
63. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan K. Aspirin for prevention of preeclampsia in women withhistorical risk factors: a systematic review. Obstet Gynecol2003; 101: 1319-32.
64. Sfar. Agents antiplaquettaires et période périopératoire. Conférence d'experts 2001. Sociéte française d'anesthésie etde réanimation; 2001.